News

UPDATE of NEW RESULTS, PROGRESS and FUTURE PLANSMonday 05-Sep-2022     12:00 – 14:00 GMTPlease contact mrcctu.stampede@ucl.ac.uk to register for the on-line meeting ...

Adding radiotherapy to standard hormone therapy helps patients with prostate cancer with limited spread of the disease, to live longer. This result from the STAMPEDE trial was published, in open access format, in the PLOS Medicine journal, in early June. For more on this story, please click on the following link to the UCL News feed:  https://www.mrcctu.ucl.ac.uk/news/news-stories/2022/june/adding-radiotherapy-can-benefit-some-patients-whose-prostate-cancer-has-spread/ ...

A five year follow-up of the STAMPEDE abiraterone comparison has been completed, and the results demonstrate that previously reported effects are robust. It shows that future results are unlikely to change meaningfully with further follow-up. The initial results of the STAMPEDE advanced prostate cancer trial showed that progression-free survival is improved when abiraterone acetate and prednisone (AAP) are added to androgen deprivation therapy. For further details related to the follow-up results, please see this article published 12th April 2022 - https://onlinelibrary.wiley.com/doi/10.1002/ijc.34018 ...

STAMPEDE

Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

See the latest News in STAMPEDE through the link to the right.